Portage Biotech Inc (PRTG) - Total Liabilities
Based on the latest financial reports, Portage Biotech Inc (PRTG) has total liabilities worth $2.01 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Portage Biotech Inc - Total Liabilities Trend (1998–2025)
This chart illustrates how Portage Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. See PRTG net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Portage Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Portage Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eyesvision Corp
KQ:031310
|
Korea | ₩101.03 Billion |
|
HOV Services Limited
NSE:HOVS
|
India | Rs154.74 Million |
|
AB Panevezio Statybos Trestas
STU:YK3
|
Germany | €57.08 Million |
|
TSR Capital Bhd
KLSE:5042
|
Malaysia | RM154.32 Million |
|
Jupiter Fund Management Plc
LSE:JUP
|
UK | GBX366.80 Million |
|
SSH GROUP LTD
F:JRSA
|
Germany | €31.15 Million |
|
WALKER RIVER RES CORP
F:1WV0
|
Germany | €562.04K |
|
Kiora Pharmaceuticals Inc
NASDAQ:KPRX
|
USA | $7.29 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Portage Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PRTG market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Portage Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Portage Biotech Inc (1998–2025)
The table below shows the annual total liabilities of Portage Biotech Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $3.05 Million | -31.42% |
| 2024-03-31 | $4.45 Million | -81.25% |
| 2023-03-31 | $23.73 Million | -18.80% |
| 2022-03-31 | $29.23 Million | +7.23% |
| 2021-03-31 | $27.26 Million | -1.00% |
| 2020-03-31 | $27.53 Million | +9.44% |
| 2019-03-31 | $25.16 Million | +6451.56% |
| 2018-03-31 | $384.00K | +24.10% |
| 2017-03-31 | $309.43K | +3.23% |
| 2016-03-31 | $299.74K | -51.70% |
| 2015-03-31 | $620.56K | +223.26% |
| 2014-03-31 | $191.97K | -57.04% |
| 2013-03-31 | $446.87K | -83.21% |
| 2012-03-31 | $2.66 Million | +289.85% |
| 2011-03-31 | $682.75K | -80.22% |
| 2010-03-31 | $3.45 Million | +2767.75% |
| 2009-03-31 | $120.39K | +109.95% |
| 2008-03-31 | $57.34K | +36.53% |
| 2007-03-31 | $42.00K | -70.32% |
| 2006-03-31 | $141.52K | +37.71% |
| 2005-03-31 | $102.77K | -84.44% |
| 2004-03-31 | $660.63K | +182.56% |
| 2003-03-31 | $233.80K | +84.85% |
| 2002-03-31 | $126.48K | +33.67% |
| 2001-03-31 | $94.62K | -37.62% |
| 2000-03-31 | $151.67K | +132.86% |
| 1999-03-31 | $65.14K | -86.89% |
| 1998-03-31 | $496.67K | -- |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more